References
- Dreyling M, Ghielmini M, Marcus R, et al.; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl. 3):iii76–iii82.
- Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
- Greco T, Landoni G, Biondi-Zoccai G, et al. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res 2013 Oct 28. [Epub ahead of print]
- NICE Clinical Guidelines, No. 92. National Clinical Guideline Centre – Acute and Chronic Conditions (UK). London: Royal College of Physicians (UK); 2010. Available from: www.ncbi.nlm.nih.gov/books/NBK116530/
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
- Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
- Messori A. Treatments for naive patients with follicular non-Hodgkin lymphoma. PubMed Commons, Published 5 December 2014. Available from: www.ncbi.nlm.nih.gov/pubmed/23433739#cm23433739_7858
- Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944–2952.
- van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
- Ghesquières H, Cartron G, Seymour JF, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012;120:2650–2657.
- Gilead Sciences.A phase 2, single arm study evaluating the safety and efficacy of idelalisib in combination with rituximab for previously untreated indolent non-Hodgkin lymphoma. NCT02258529. Available from: https://clinicaltrials.gov
- Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014;15:1311–1318.